Short-Term Safety of Booster Immunization With BNT162b2 mRNA COVID-19 Vaccine in Healthcare Workers
Yael Paran, Esther Saiag, Avishay Spitzer, Yoel Angel, Michal Yakubovsky, Hagit Padova, Ronen Ben‐Ami, Ilana Goldinger, Ronni Gamzu, Eli Sprecher, David Zeltser, Oryan Henig
Abstract
This study demonstrated a favorable short-term safety profile after a third dose of the BNT162b2 vaccine among healthcare workers (HCWs). There were more frequent local reactions and less systemic reactions compared to the second dose. The HCWs who reported reactions had higher prebooster titer of anti-S1 antibodies compared to those who reported no reactions.
Topics & Concepts
MedicineBooster (rocketry)ImmunizationCoronavirus disease 2019 (COVID-19)Booster doseTiterSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Health care2019-20 coronavirus outbreakVirologyAntibodyImmunologyInternal medicineInfectious disease (medical specialty)OutbreakAstronomyPhysicsEconomicsEconomic growthDiseaseSARS-CoV-2 and COVID-19 ResearchVaccine Coverage and HesitancyBacillus and Francisella bacterial research